Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 0.51 |
| ▸ | CSF1R | P07333 | 11/20 | 0.51 |
| ▸ | FLT3 | P36888 | 5/20 | 0.51 |
| ▸ | KIT | P10721 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25255415 | 0.84 | KDR (0.54) | KDRCSF1RFLT3KITCYP2D6 | |
| SCHEMBL29450848 | 0.84 | KDR (0.54) | KDRCSF1RFLT3KITCYP2D6 | |
| SCHEMBL731130 | 0.84 | KDR (0.70) | KDRCSF1RFLT3KITCYP2D6 | |
| SCHEMBL25293765 | 0.84 | KDR (0.50) | KDRCSF1RFLT3KITCYP2D6 | |
| SCHEMBL27045657 | 0.83 | KDR (0.51) | KDRCSF1RFLT3KITCYP2D6 | |
| SCHEMBL30440917 | 0.76 | FLT3 (0.59) | KDRCSF1RFLT3KITCYP2D6 | |
| SCHEMBL27030689 | 0.76 | FLT3 (0.59) | KDRCSF1RFLT3KITCYP2D6 | |
| SCHEMBL25292270 | 0.75 | FLT3 (0.46) | KDRCSF1RFLT3KITCYP2D6 | |
| SCHEMBL29450836 | 0.75 | FLT3 (0.60) | FLT3 | |
| SCHEMBL4682250 | 0.75 | FLT3 (0.60) | FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600719-B2 | Salt inducible kinase inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4660192-A1 | SALT INDUCIBLE KINASE INHIBITORS | The General Hospital Corporation (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION | 2024-01-25 | — | — | US | disclosed |
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION | 2024-01-25 | — | — | US | disclosed |
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION | 2024-01-25 | — | — | US | disclosed |
| EP-4192459-A1 | SALT INDUCIBLE KINASE INHIBITORS | The General Hospital Corporation (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022031928-A1 | SALT INDUCIBLE KINASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600719-B2 | Salt inducible kinase inhibitors | GRK6, SGK1, CSNK1A1 | KDR 1018/4885CSF1R 3035/4885FLT3 2994/4885 |
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | SGK1, SGK2, SIK1 | KDR 2083/4885CSF1R 2228/4885FLT3 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.